Laddar populära aktier...
DexTech Medical AB, Bulletin from the Annual General Meeting
DexTech Medical AB, Kommuniké från årsstämma
DexTech Medical AB, Interim report July 1- September 30, 2024
DexTech Medical AB Delårsrapport 1 juli, – 30 september 2024
DexTech Medical AB, Invitation to open Annual General Meeting and notice
DexTech Medical AB, Inbjudan till öppen årsstämma samt kallelse
DexTech Medical AB: Annual Report 2023-07-01 - 2024-06-30
DexTech Medical AB: Årsredovisning 2023-07-01 - 2024-06-30
DexTech Medical AB, Year-end report July 1, 2023 - June 30, 2024
DexTech Medical AB, Bokslutskommuniké 1 juli, 2023 – 30 juni 2024
DexTech Medical AB announces continued positive results from myeloma study
DexTech Medical AB meddelar fortsatt positiva resultat från myelomstudien
DexTech Medical AB, Interim report July 1, 2023 - March 31, 2024
DexTech Medical AB, Delårsrapport 1 juli, 2023 – 31 mars 2024
The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM).
Fas 1 studien undersöker OsteoDex effekt på patienter med progressiv multipelt myelom (MM).
Correction: Due to MAR label being wrongly included in the report.
Rättelse: På grund av att MAR-etikett felaktigt kom med i rapporten.
DexTech Medical AB, Half-year report July 1 - December 31, 2023
DexTech Medical AB, Halvårsrapport 1 juli – 31 december 2023
The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX).
De första provsvaren från patient 1 har inkommit och visar en mycket stark effekt på markören för osteoklast aktivitet (CTX).
DexTech Medical AB, Interim report July 1 - September 30, 2023
DexTech Medical AB, Delårsrapport 1 juli, – 30 september 2023
DexTech Medical files a new patent application with the European Patent Office
DexTech Medical lämnar in ny patentansökan till Europeiska Patentverket
DexTech Medical AB: Annual Report 2022-07-01 - 2023-06-30
DexTech Medical AB: Årsredovisning 2022-07-01 - 2023-06-30
DexTech Medical AB, Year-end report July 1, 2021 - June 30, 2022
DexTech Medical AB, Bokslutskommuniké 1 juli, 2022 – 30 juni 2023
DexTech Medical AB Interim report July 1, 2022 - March 31, 2023
DexTech Medical AB Delårsrapport 1 juli, 2022 – 31 mars 2023
DexTech Medical AB informs about the myeloma study
DexTech Medical AB informerar om myelomstudien
DexTech Medical AB, Halvårsrapport 1 juli – 31 december 2022
DexTech Medical AB, Half-year report July 1 - December 31, 2022
DexTech Medical beslutar om tilldelning avseende incitamentsprogram
DexTech Medical decision on allocation regarding incentive programs
DexTech Medical AB, Delårsrapport 1 juli, 2022 – 30 september 2022
DexTech Medical AB, Interim report July 1 - September 30, 2022
Trots den allmänna kursmässiga holmgången fortsätter utvecklingsarbetet oförtrutet i börsens många biotechbolag.
WELCOME TO THE ANNUAL GENERAL MEETING 2022 IN DEXTECH MEDICAL AB (publ)
VÄLKOMMEN TILL ÅRSSTÄMMA 2022 I DEXTECH MEDICAL AB (publ)
DexTech Medical announces upcoming multiple myeloma study
DexTech Medical informerar om kommande multipelt myelom-studie
DexTech Medical AB: Annual Report 2021-07-01 - 2022-06-30
DexTech Medical AB: Årsredovisning 2021-07-01 - 2022-06-30
DexTech Medical AB, Bokslutskommuniké 1 juli 2021 – 30 juni 2022
DexTech Medical's application for myeloma study approved
DexTech Medicals ansökan för myelom-studie godkänd
Uppsala-based DexTech are now preparing for the proof-of-concept study that will evaluate the drug candidate OsteoDex for the treatment of m...
Uppsalabaserade DexTech är i full gång med förberedelserna inför proof-of-concept-studien som ska utvärdera läkemedelskandidaten OsteoDex fö...
DexTech Medical AB, Kommuniké från extra bolagsstämma
DexTech Medical AB, Report from the Extraordinary General Meeting
DexTech Medical AB, Interim report July 1, 2021 - March 31, 2022
DexTech Medical AB, Delårsrapport 1 juli, 2021 – 31 mars 2022
With positive phase II data in castration-resistant prostate cancer and upcoming studies in multiple myeloma, DexTech is now taking further ...
Med positiva fas II-data i kastrationsresistent prostatacancer och föreståendestudier inom multipelt myelom tar DexTech nu ytterligare steg ...
Kallelse till extra bolagsstämma i DexTech Medical AB
Notice of Extraordinary General Meeting in DexTech Medical AB
DexTech Medical strengthens its organization, Andreas Segerros proposed as new Chairman of the Board
DexTech Medical stärker sin organisation, föreslår Andreas Segerros som ny styrelseordförande
The stock market turbulence of recent months has also left its mark on the biotechnology sector, and one of many companies affected is DexTe...
De senaste månadernas börsturbulens har satt sina spår även i biotekniksektorn och ett av många bolag som påverkats är DexTech, vars aktie t...
DexTech Medical develops drug candidates in oncology that are based on the CDC platform GuaDex, where different substances are combined with...
Rapportaktuella DexTech Medical utvecklar läkemedelskandidater inom onkologi som tar avstamp i CDC-plattformen GuaDex, där olika substanser ...
Correction, in the English version that was sent out recently, the MAR label and contact details were not attached, but they are now attache...
DexTech Medical AB, Half-year report July 1 - December 31, 2021
DexTech Medical AB, Last day of trading in BTA
Dextech Medical AB, Sista dag för handel med BTA
DexTech Medical AB meddelar utfall i genomförd företrädesemission
DexTech Medical AB announces outcome of finalized rights issue
Efter solida fas II-data för OsteoDex i metastaserad kastrationsresistent prostatacancer flyttar Uppsalabaserade DexTech fram positionerna.
Today, the subscription period for DexTech Medical AB's rights issue begins
Idag inleds teckningsperioden i DexTech Medical AB:s företrädesemission
Uppsalabaserade DexTechs huvudkandidat OsteoDex ligger i långt framskriden klinisk utvecklingsfas.
DexTech Medical AB announces prospectus due to upcoming rights issue
DexTech Medical AB offentliggör prospekt med anledning av kommande företrädesemission
Report from the Extraordinary General Meeting in DexTech Medical AB
Kommuniké från extra bolagsstämma i DexTech Medical AB
DexTech Medical AB, Report from the Annual General Meeting
Notice of extraordinary general meeting of DexTech Medical AB
The Board of Directors of DexTech proposes a rights issue of approx.
Styrelsen i DexTech föreslår en företrädesemission om cirka 58,2 MSEK i syfte att vidareutveckla projektet med multipelt myelom till klinisk...
DexTech Medical AB Interim report July 1 2021 - September 30, 2021
DexTech Medical AB, Delårsrapport 1 juli 2021 – 30 september 2021
DexTech Medical AB strengthens board ahead of myeloma study
